摘要 |
The invention provides compounds of the formula: (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R<l >and NR<2>R<3> and a maximum chain length of 4 atoms extending between E and NR<2>R<3>, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the inker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NR<2>R<3> group and provided that the oxo group when present is located at a carbon atom a with respect to the NR<2>R<3> group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; R<l> is an aryl or heteroaryl group; and R<2>, R<3>, R<4> and R<5> are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents. |
申请人 |
ASTEX TECHNOLOGY LIMITED;CANCER RESEARCH TECHNOLOGY LIMITED;THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL;BERDINI, VALERIO;SAXTY, GORDON;VERDONK, MARINUS, LEENDERT;WOODHEAD, STEVEN, JOHN;WYATT, PAUL, GRAHAM;BOYLE, ROBERT, GEORGE;SORE, HANNAH, FIONA;WALKER, DAVID, WINTER;COLLINS, IAN;DOWNHAM, ROBERT;CARR, ROBIN, ARTHUR, ELLIS |
发明人 |
BERDINI, VALERIO;SAXTY, GORDON;VERDONK, MARINUS, LEENDERT;WOODHEAD, STEVEN, JOHN;WYATT, PAUL, GRAHAM;BOYLE, ROBERT, GEORGE;SORE, HANNAH, FIONA;WALKER, DAVID, WINTER;COLLINS, IAN;DOWNHAM, ROBERT;CARR, ROBIN, ARTHUR, ELLIS |